nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR1A—stomach cancer	0.624	1	CbGaD
Lurasidone—HTR7—myenteric nerve plexus—stomach cancer	0.0159	0.175	CbGeAlD
Lurasidone—HTR7—vagus nerve—stomach cancer	0.0106	0.117	CbGeAlD
Lurasidone—HTR7—vein—stomach cancer	0.0103	0.113	CbGeAlD
Lurasidone—HTR2A—myenteric nerve plexus—stomach cancer	0.00993	0.109	CbGeAlD
Lurasidone—HTR2A—vagus nerve—stomach cancer	0.00662	0.0729	CbGeAlD
Lurasidone—HTR2A—vein—stomach cancer	0.0064	0.0705	CbGeAlD
Lurasidone—HTR7—blood vessel—stomach cancer	0.00326	0.0358	CbGeAlD
Lurasidone—HTR2A—blood vessel—stomach cancer	0.00203	0.0224	CbGeAlD
Lurasidone—HTR1A—hematopoietic system—stomach cancer	0.00181	0.02	CbGeAlD
Lurasidone—HTR7—hematopoietic system—stomach cancer	0.00173	0.0191	CbGeAlD
Lurasidone—HTR7—epithelium—stomach cancer	0.00159	0.0174	CbGeAlD
Lurasidone—HTR7—smooth muscle tissue—stomach cancer	0.00153	0.0168	CbGeAlD
Lurasidone—ADRA2C—pancreas—stomach cancer	0.0013	0.0143	CbGeAlD
Lurasidone—ADRA2A—hematopoietic system—stomach cancer	0.00127	0.014	CbGeAlD
Lurasidone—HTR7—digestive system—stomach cancer	0.00121	0.0133	CbGeAlD
Lurasidone—HTR2A—hematopoietic system—stomach cancer	0.00108	0.0119	CbGeAlD
Lurasidone—HTR1A—endocrine gland—stomach cancer	0.00104	0.0115	CbGeAlD
Lurasidone—ADRA2A—pancreas—stomach cancer	0.00104	0.0114	CbGeAlD
Lurasidone—CYP3A4—hematopoietic system—stomach cancer	0.001	0.011	CbGeAlD
Lurasidone—HTR7—endocrine gland—stomach cancer	0.000996	0.011	CbGeAlD
Lurasidone—HTR2A—epithelium—stomach cancer	0.000988	0.0109	CbGeAlD
Lurasidone—HTR2A—smooth muscle tissue—stomach cancer	0.000952	0.0105	CbGeAlD
Lurasidone—Ziprasidone—HTR1A—stomach cancer	0.000951	1	CrCbGaD
Lurasidone—DRD2—endocrine gland—stomach cancer	0.000942	0.0104	CbGeAlD
Lurasidone—HTR7—liver—stomach cancer	0.000898	0.00989	CbGeAlD
Lurasidone—ADRA2C—liver—stomach cancer	0.000826	0.00909	CbGeAlD
Lurasidone—HTR2A—digestive system—stomach cancer	0.000752	0.00828	CbGeAlD
Lurasidone—ADRA2A—endocrine gland—stomach cancer	0.000731	0.00805	CbGeAlD
Lurasidone—CYP3A4—digestive system—stomach cancer	0.000696	0.00766	CbGeAlD
Lurasidone—ADRA2C—lymph node—stomach cancer	0.000633	0.00697	CbGeAlD
Lurasidone—HTR2A—endocrine gland—stomach cancer	0.000621	0.00684	CbGeAlD
Lurasidone—CYP3A4—endocrine gland—stomach cancer	0.000575	0.00633	CbGeAlD
Lurasidone—HTR2A—liver—stomach cancer	0.00056	0.00617	CbGeAlD
Lurasidone—CYP3A4—liver—stomach cancer	0.000519	0.00571	CbGeAlD
Lurasidone—ADRA2A—lymph node—stomach cancer	0.000505	0.00556	CbGeAlD
Lurasidone—Neutropenia—Epirubicin—stomach cancer	0.00025	0.00126	CcSEcCtD
Lurasidone—Dysuria—Epirubicin—stomach cancer	0.00025	0.00126	CcSEcCtD
Lurasidone—Syncope—Docetaxel—stomach cancer	0.000248	0.00125	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—stomach cancer	0.000247	0.00125	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—stomach cancer	0.000247	0.00125	CcSEcCtD
Lurasidone—Leukopenia—Docetaxel—stomach cancer	0.000247	0.00125	CcSEcCtD
Lurasidone—Anaemia—Capecitabine—stomach cancer	0.000247	0.00125	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—stomach cancer	0.000245	0.00124	CcSEcCtD
Lurasidone—Weight increased—Epirubicin—stomach cancer	0.000243	0.00123	CcSEcCtD
Lurasidone—Loss of consciousness—Docetaxel—stomach cancer	0.000243	0.00123	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—stomach cancer	0.000241	0.00122	CcSEcCtD
Lurasidone—Malaise—Capecitabine—stomach cancer	0.000241	0.00122	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—stomach cancer	0.000241	0.00122	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—stomach cancer	0.000241	0.00122	CcSEcCtD
Lurasidone—Vertigo—Capecitabine—stomach cancer	0.00024	0.00121	CcSEcCtD
Lurasidone—Syncope—Capecitabine—stomach cancer	0.00024	0.00121	CcSEcCtD
Lurasidone—Leukopenia—Capecitabine—stomach cancer	0.000239	0.00121	CcSEcCtD
Lurasidone—Convulsion—Docetaxel—stomach cancer	0.000239	0.00121	CcSEcCtD
Lurasidone—Hypertension—Docetaxel—stomach cancer	0.000238	0.0012	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—stomach cancer	0.000238	0.0012	CcSEcCtD
Lurasidone—Infestation—Epirubicin—stomach cancer	0.000238	0.0012	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—stomach cancer	0.000238	0.0012	CcSEcCtD
Lurasidone—Myalgia—Docetaxel—stomach cancer	0.000235	0.00119	CcSEcCtD
Lurasidone—Loss of consciousness—Capecitabine—stomach cancer	0.000235	0.00119	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—stomach cancer	0.000234	0.00118	CcSEcCtD
Lurasidone—Asthenia—Irinotecan—stomach cancer	0.000234	0.00118	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000234	0.00118	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—stomach cancer	0.000232	0.00117	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—stomach cancer	0.000231	0.00117	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—stomach cancer	0.000231	0.00117	CcSEcCtD
Lurasidone—Hypertension—Capecitabine—stomach cancer	0.000231	0.00117	CcSEcCtD
Lurasidone—Dry mouth—Docetaxel—stomach cancer	0.00023	0.00116	CcSEcCtD
Lurasidone—Myalgia—Capecitabine—stomach cancer	0.000228	0.00115	CcSEcCtD
Lurasidone—Anxiety—Capecitabine—stomach cancer	0.000227	0.00115	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000226	0.00114	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—stomach cancer	0.000226	0.00114	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—stomach cancer	0.000225	0.00114	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—stomach cancer	0.000225	0.00114	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—stomach cancer	0.000224	0.00113	CcSEcCtD
Lurasidone—Infection—Docetaxel—stomach cancer	0.000224	0.00113	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—stomach cancer	0.000223	0.00113	CcSEcCtD
Lurasidone—Diarrhoea—Irinotecan—stomach cancer	0.000223	0.00113	CcSEcCtD
Lurasidone—Dry mouth—Capecitabine—stomach cancer	0.000223	0.00112	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—stomach cancer	0.000223	0.00112	CcSEcCtD
Lurasidone—Shock—Docetaxel—stomach cancer	0.000222	0.00112	CcSEcCtD
Lurasidone—Nervous system disorder—Docetaxel—stomach cancer	0.000221	0.00112	CcSEcCtD
Lurasidone—Pruritus—Fluorouracil—stomach cancer	0.000221	0.00112	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—stomach cancer	0.000221	0.00111	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—stomach cancer	0.000221	0.00111	CcSEcCtD
Lurasidone—Tachycardia—Docetaxel—stomach cancer	0.00022	0.00111	CcSEcCtD
Lurasidone—Skin disorder—Docetaxel—stomach cancer	0.000219	0.00111	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—stomach cancer	0.000218	0.0011	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—stomach cancer	0.000217	0.0011	CcSEcCtD
Lurasidone—Infection—Capecitabine—stomach cancer	0.000217	0.0011	CcSEcCtD
Lurasidone—Dizziness—Irinotecan—stomach cancer	0.000216	0.00109	CcSEcCtD
Lurasidone—Shock—Capecitabine—stomach cancer	0.000215	0.00108	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—stomach cancer	0.000214	0.00108	CcSEcCtD
Lurasidone—Nervous system disorder—Capecitabine—stomach cancer	0.000214	0.00108	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—stomach cancer	0.000214	0.00108	CcSEcCtD
Lurasidone—Diarrhoea—Fluorouracil—stomach cancer	0.000214	0.00108	CcSEcCtD
Lurasidone—Tachycardia—Capecitabine—stomach cancer	0.000213	0.00108	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—stomach cancer	0.000212	0.00107	CcSEcCtD
Lurasidone—Skin disorder—Capecitabine—stomach cancer	0.000212	0.00107	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—stomach cancer	0.000211	0.00107	CcSEcCtD
Lurasidone—Hyperhidrosis—Capecitabine—stomach cancer	0.000211	0.00107	CcSEcCtD
Lurasidone—Hypotension—Docetaxel—stomach cancer	0.000211	0.00106	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—stomach cancer	0.00021	0.00106	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—stomach cancer	0.00021	0.00106	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—stomach cancer	0.000209	0.00105	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—stomach cancer	0.000208	0.00105	CcSEcCtD
Lurasidone—Vomiting—Irinotecan—stomach cancer	0.000207	0.00105	CcSEcCtD
Lurasidone—Dizziness—Fluorouracil—stomach cancer	0.000207	0.00104	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—stomach cancer	0.000206	0.00104	CcSEcCtD
Lurasidone—Rash—Irinotecan—stomach cancer	0.000206	0.00104	CcSEcCtD
Lurasidone—Dermatitis—Irinotecan—stomach cancer	0.000205	0.00104	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000205	0.00104	CcSEcCtD
Lurasidone—Hypotension—Capecitabine—stomach cancer	0.000204	0.00103	CcSEcCtD
Lurasidone—Insomnia—Docetaxel—stomach cancer	0.000204	0.00103	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—stomach cancer	0.000202	0.00102	CcSEcCtD
Lurasidone—Dyspnoea—Docetaxel—stomach cancer	0.000201	0.00102	CcSEcCtD
Lurasidone—Somnolence—Docetaxel—stomach cancer	0.0002	0.00101	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—stomach cancer	0.0002	0.00101	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—stomach cancer	0.0002	0.00101	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—stomach cancer	0.000199	0.00101	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000199	0.001	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—stomach cancer	0.000199	0.001	CcSEcCtD
Lurasidone—Vomiting—Fluorouracil—stomach cancer	0.000199	0.001	CcSEcCtD
Lurasidone—Dyspepsia—Docetaxel—stomach cancer	0.000198	0.001	CcSEcCtD
Lurasidone—Insomnia—Capecitabine—stomach cancer	0.000197	0.000997	CcSEcCtD
Lurasidone—Rash—Fluorouracil—stomach cancer	0.000197	0.000995	CcSEcCtD
Lurasidone—Dermatitis—Fluorouracil—stomach cancer	0.000197	0.000994	CcSEcCtD
Lurasidone—Decreased appetite—Docetaxel—stomach cancer	0.000196	0.00099	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—stomach cancer	0.000196	0.000988	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000195	0.000983	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—stomach cancer	0.000195	0.000983	CcSEcCtD
Lurasidone—Dyspnoea—Capecitabine—stomach cancer	0.000195	0.000983	CcSEcCtD
Lurasidone—Fatigue—Docetaxel—stomach cancer	0.000194	0.000982	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—stomach cancer	0.000194	0.000981	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—stomach cancer	0.000194	0.000981	CcSEcCtD
Lurasidone—Nausea—Irinotecan—stomach cancer	0.000194	0.000978	CcSEcCtD
Lurasidone—Back pain—Methotrexate—stomach cancer	0.000193	0.000973	CcSEcCtD
Lurasidone—Dyspepsia—Capecitabine—stomach cancer	0.000192	0.00097	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—stomach cancer	0.000191	0.000966	CcSEcCtD
Lurasidone—Decreased appetite—Capecitabine—stomach cancer	0.00019	0.000958	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000188	0.000952	CcSEcCtD
Lurasidone—Fatigue—Capecitabine—stomach cancer	0.000188	0.000951	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—stomach cancer	0.000188	0.000948	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—stomach cancer	0.000188	0.000947	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—stomach cancer	0.000186	0.000941	CcSEcCtD
Lurasidone—Nausea—Fluorouracil—stomach cancer	0.000186	0.000937	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—stomach cancer	0.000185	0.000935	CcSEcCtD
Lurasidone—Gastrointestinal pain—Docetaxel—stomach cancer	0.000184	0.000931	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—stomach cancer	0.000184	0.000929	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—stomach cancer	0.000184	0.000928	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—stomach cancer	0.000184	0.000927	CcSEcCtD
Lurasidone—Back pain—Epirubicin—stomach cancer	0.00018	0.00091	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—stomach cancer	0.00018	0.000908	CcSEcCtD
Lurasidone—Malaise—Methotrexate—stomach cancer	0.00018	0.000907	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—stomach cancer	0.000179	0.000905	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—stomach cancer	0.000179	0.000903	CcSEcCtD
Lurasidone—Gastrointestinal pain—Capecitabine—stomach cancer	0.000178	0.000902	CcSEcCtD
Lurasidone—Abdominal pain—Docetaxel—stomach cancer	0.000178	0.0009	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—stomach cancer	0.000178	0.0009	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—stomach cancer	0.000177	0.000894	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—stomach cancer	0.000176	0.000887	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—stomach cancer	0.000174	0.000876	CcSEcCtD
Lurasidone—Abdominal pain—Capecitabine—stomach cancer	0.000173	0.000872	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—stomach cancer	0.000173	0.000871	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—stomach cancer	0.000172	0.000871	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—stomach cancer	0.000172	0.00087	CcSEcCtD
Lurasidone—Agitation—Epirubicin—stomach cancer	0.000171	0.000865	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—stomach cancer	0.00017	0.000858	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—stomach cancer	0.00017	0.000856	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000168	0.00085	CcSEcCtD
Lurasidone—Malaise—Epirubicin—stomach cancer	0.000168	0.000849	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—stomach cancer	0.000167	0.000846	CcSEcCtD
Lurasidone—Syncope—Epirubicin—stomach cancer	0.000167	0.000844	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—stomach cancer	0.000167	0.000842	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—stomach cancer	0.000167	0.000842	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—stomach cancer	0.000166	0.000837	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—stomach cancer	0.000164	0.000827	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—stomach cancer	0.000162	0.000821	CcSEcCtD
Lurasidone—Asthenia—Docetaxel—stomach cancer	0.000162	0.000817	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—stomach cancer	0.000161	0.000815	CcSEcCtD
Lurasidone—Infection—Methotrexate—stomach cancer	0.000161	0.000815	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—stomach cancer	0.000161	0.000812	CcSEcCtD
Lurasidone—Pruritus—Docetaxel—stomach cancer	0.00016	0.000806	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—stomach cancer	0.000159	0.000805	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—stomach cancer	0.000159	0.000805	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—stomach cancer	0.000159	0.000801	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—stomach cancer	0.000158	0.0008	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—stomach cancer	0.000158	0.000798	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—stomach cancer	0.000158	0.000797	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000158	0.000796	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—stomach cancer	0.000157	0.000793	CcSEcCtD
Lurasidone—Asthenia—Capecitabine—stomach cancer	0.000157	0.000791	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—stomach cancer	0.000155	0.000785	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—stomach cancer	0.000155	0.000784	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—stomach cancer	0.000155	0.000782	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—stomach cancer	0.000155	0.000781	CcSEcCtD
Lurasidone—Pruritus—Capecitabine—stomach cancer	0.000154	0.00078	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—stomach cancer	0.000154	0.000779	CcSEcCtD
Lurasidone—Diarrhoea—Docetaxel—stomach cancer	0.000154	0.000779	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—stomach cancer	0.000152	0.000767	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—stomach cancer	0.000152	0.000765	CcSEcCtD
Lurasidone—Infection—Epirubicin—stomach cancer	0.000151	0.000763	CcSEcCtD
Lurasidone—Shock—Epirubicin—stomach cancer	0.00015	0.000756	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—stomach cancer	0.000149	0.000754	CcSEcCtD
Lurasidone—Diarrhoea—Capecitabine—stomach cancer	0.000149	0.000754	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—stomach cancer	0.000149	0.000753	CcSEcCtD
Lurasidone—Dizziness—Docetaxel—stomach cancer	0.000149	0.000753	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—stomach cancer	0.000149	0.000752	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—stomach cancer	0.000148	0.00075	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000148	0.000748	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—stomach cancer	0.000148	0.000746	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—stomach cancer	0.000147	0.000742	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—stomach cancer	0.000147	0.000742	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—stomach cancer	0.000147	0.000741	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—stomach cancer	0.000146	0.000739	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000146	0.000736	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—stomach cancer	0.000145	0.000732	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—stomach cancer	0.000144	0.00073	CcSEcCtD
Lurasidone—Dizziness—Capecitabine—stomach cancer	0.000144	0.000729	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—stomach cancer	0.000144	0.000725	CcSEcCtD
Lurasidone—Vomiting—Docetaxel—stomach cancer	0.000143	0.000724	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—stomach cancer	0.000143	0.000722	CcSEcCtD
Lurasidone—Rash—Docetaxel—stomach cancer	0.000142	0.000718	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—stomach cancer	0.000142	0.000718	CcSEcCtD
Lurasidone—Dermatitis—Docetaxel—stomach cancer	0.000142	0.000717	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—stomach cancer	0.000141	0.000713	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—stomach cancer	0.00014	0.000709	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—stomach cancer	0.00014	0.000708	CcSEcCtD
Lurasidone—Infection—Doxorubicin—stomach cancer	0.00014	0.000706	CcSEcCtD
Lurasidone—Vomiting—Capecitabine—stomach cancer	0.000139	0.000701	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000139	0.0007	CcSEcCtD
Lurasidone—Shock—Doxorubicin—stomach cancer	0.000138	0.000699	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—stomach cancer	0.000138	0.000697	CcSEcCtD
Lurasidone—Rash—Capecitabine—stomach cancer	0.000138	0.000695	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—stomach cancer	0.000138	0.000695	CcSEcCtD
Lurasidone—Dermatitis—Capecitabine—stomach cancer	0.000138	0.000694	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—stomach cancer	0.000137	0.000694	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—stomach cancer	0.000137	0.00069	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—stomach cancer	0.000136	0.000687	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—stomach cancer	0.000136	0.000685	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—stomach cancer	0.000135	0.000683	CcSEcCtD
Lurasidone—Nausea—Docetaxel—stomach cancer	0.000134	0.000676	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—stomach cancer	0.000134	0.000676	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—stomach cancer	0.000133	0.000671	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—stomach cancer	0.000132	0.000668	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—stomach cancer	0.000131	0.000664	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000131	0.000663	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—stomach cancer	0.000131	0.000662	CcSEcCtD
Lurasidone—Nausea—Capecitabine—stomach cancer	0.00013	0.000655	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—stomach cancer	0.000128	0.000649	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000128	0.000647	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—stomach cancer	0.000127	0.000643	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—stomach cancer	0.000125	0.000634	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—stomach cancer	0.000125	0.000632	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—stomach cancer	0.000124	0.000628	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—stomach cancer	0.000124	0.000626	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—stomach cancer	0.000122	0.000618	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000121	0.000614	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—stomach cancer	0.000121	0.000613	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—stomach cancer	0.00012	0.000607	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—stomach cancer	0.000117	0.000589	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000115	0.000581	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—stomach cancer	0.000115	0.000581	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—stomach cancer	0.000111	0.000562	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—stomach cancer	0.000111	0.000562	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—stomach cancer	0.000109	0.000551	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—stomach cancer	0.000108	0.000543	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—stomach cancer	0.000107	0.000543	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—stomach cancer	0.000104	0.000526	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—stomach cancer	0.000103	0.000522	CcSEcCtD
Lurasidone—Rash—Methotrexate—stomach cancer	0.000102	0.000517	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—stomach cancer	0.000102	0.000517	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—stomach cancer	0.000101	0.00051	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—stomach cancer	0.000101	0.000508	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—stomach cancer	9.95e-05	0.000503	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—stomach cancer	9.67e-05	0.000488	CcSEcCtD
Lurasidone—Nausea—Methotrexate—stomach cancer	9.65e-05	0.000487	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—stomach cancer	9.63e-05	0.000486	CcSEcCtD
Lurasidone—Rash—Epirubicin—stomach cancer	9.59e-05	0.000484	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—stomach cancer	9.58e-05	0.000484	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—stomach cancer	9.3e-05	0.00047	CcSEcCtD
Lurasidone—Nausea—Epirubicin—stomach cancer	9.03e-05	0.000456	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—stomach cancer	8.95e-05	0.000452	CcSEcCtD
Lurasidone—Rash—Doxorubicin—stomach cancer	8.87e-05	0.000448	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—stomach cancer	8.86e-05	0.000448	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—stomach cancer	8.36e-05	0.000422	CcSEcCtD
Lurasidone—ADRA2C—Signaling Pathways—IRS2—stomach cancer	1.18e-05	0.000136	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APOA1—stomach cancer	1.18e-05	0.000136	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CXCL8—stomach cancer	1.17e-05	0.000135	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SMAD4—stomach cancer	1.17e-05	0.000135	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FGFR2—stomach cancer	1.16e-05	0.000134	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—PIK3CA—stomach cancer	1.16e-05	0.000134	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CXCL8—stomach cancer	1.16e-05	0.000133	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CXCL8—stomach cancer	1.16e-05	0.000133	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FGFR2—stomach cancer	1.15e-05	0.000132	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—PIK3CA—stomach cancer	1.15e-05	0.000132	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CAV1—stomach cancer	1.14e-05	0.000131	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APOA1—stomach cancer	1.14e-05	0.000131	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ERBB2—stomach cancer	1.12e-05	0.00013	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TP53—stomach cancer	1.12e-05	0.00013	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALDOB—stomach cancer	1.12e-05	0.00013	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PRKCB—stomach cancer	1.12e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6ST—stomach cancer	1.12e-05	0.000129	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FYN—stomach cancer	1.11e-05	0.000128	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CAV1—stomach cancer	1.11e-05	0.000128	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—APOA1—stomach cancer	1.1e-05	0.000127	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PRKCB—stomach cancer	1.09e-05	0.000125	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6ST—stomach cancer	1.08e-05	0.000125	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ALB—stomach cancer	1.08e-05	0.000124	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—HRAS—stomach cancer	1.08e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APC—stomach cancer	1.07e-05	0.000124	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IRS2—stomach cancer	1.07e-05	0.000123	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCL8—stomach cancer	1.07e-05	0.000123	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—HRAS—stomach cancer	1.06e-05	0.000122	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCL8—stomach cancer	1.05e-05	0.000121	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IRS2—stomach cancer	1.05e-05	0.000121	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALOX5—stomach cancer	1.04e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FGFR2—stomach cancer	1.04e-05	0.00012	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CDKN1B—stomach cancer	1.04e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APC—stomach cancer	1.04e-05	0.00012	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CAV1—stomach cancer	1.03e-05	0.000119	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APOA1—stomach cancer	1.03e-05	0.000119	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—NOS3—stomach cancer	1.03e-05	0.000119	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—MAPK3—stomach cancer	1.03e-05	0.000118	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—DPYD—stomach cancer	1.03e-05	0.000118	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CAV1—stomach cancer	1.02e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APOA1—stomach cancer	1.02e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL6—stomach cancer	1.01e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6R—stomach cancer	9.96e-06	0.000115	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—MAPK3—stomach cancer	9.94e-06	0.000115	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCND1—stomach cancer	9.93e-06	0.000115	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—JUN—stomach cancer	9.91e-06	0.000114	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PRKCB—stomach cancer	9.84e-06	0.000114	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6ST—stomach cancer	9.81e-06	0.000113	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—MAPK1—stomach cancer	9.78e-06	0.000113	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—EGFR—stomach cancer	9.78e-06	0.000113	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARG—stomach cancer	9.73e-06	0.000112	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PRKCB—stomach cancer	9.69e-06	0.000112	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6ST—stomach cancer	9.65e-06	0.000111	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MMP9—stomach cancer	9.64e-06	0.000111	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6R—stomach cancer	9.64e-06	0.000111	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CDKN1A—stomach cancer	9.61e-06	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IRS2—stomach cancer	9.55e-06	0.00011	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—MAPK1—stomach cancer	9.46e-06	0.000109	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—EGFR—stomach cancer	9.46e-06	0.000109	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTGS2—stomach cancer	9.43e-06	0.000109	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APC—stomach cancer	9.42e-06	0.000109	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK8—stomach cancer	9.38e-06	0.000108	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—PIK3CA—stomach cancer	9.34e-06	0.000108	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SERPINE1—stomach cancer	9.33e-06	0.000108	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APC—stomach cancer	9.27e-06	0.000107	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CAV1—stomach cancer	9.26e-06	0.000107	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APOA1—stomach cancer	9.24e-06	0.000107	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—KRAS—stomach cancer	9.24e-06	0.000106	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTT1—stomach cancer	9.09e-06	0.000105	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PIK3CA—stomach cancer	9.04e-06	0.000104	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SERPINE1—stomach cancer	9.03e-06	0.000104	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—MAPK3—stomach cancer	9.02e-06	0.000104	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—RHOA—stomach cancer	9e-06	0.000104	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2A6—stomach cancer	8.98e-06	0.000104	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—stomach cancer	8.94e-06	0.000103	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOS3—stomach cancer	8.91e-06	0.000103	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK3—stomach cancer	8.88e-06	0.000102	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PRKCB—stomach cancer	8.81e-06	0.000102	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6ST—stomach cancer	8.78e-06	0.000101	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—stomach cancer	8.75e-06	0.000101	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6R—stomach cancer	8.75e-06	0.000101	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKR1C3—stomach cancer	8.74e-06	0.000101	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—RHOA—stomach cancer	8.71e-06	0.0001	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—stomach cancer	8.66e-06	9.98e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOS3—stomach cancer	8.62e-06	9.94e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6R—stomach cancer	8.61e-06	9.92e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—MAPK1—stomach cancer	8.59e-06	9.9e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—stomach cancer	8.58e-06	9.9e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—stomach cancer	8.57e-06	9.89e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ENO1—stomach cancer	8.51e-06	9.82e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—stomach cancer	8.49e-06	9.78e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK1—stomach cancer	8.45e-06	9.74e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—stomach cancer	8.45e-06	9.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APC—stomach cancer	8.43e-06	9.72e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NOS3—stomach cancer	8.37e-06	9.65e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—stomach cancer	8.33e-06	9.61e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—stomach cancer	8.21e-06	9.47e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—stomach cancer	8.2e-06	9.46e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK3—stomach cancer	8.19e-06	9.44e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SERPINE1—stomach cancer	8.19e-06	9.44e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—stomach cancer	8.11e-06	9.35e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK3—stomach cancer	8.08e-06	9.31e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—stomach cancer	8.07e-06	9.31e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—stomach cancer	8.06e-06	9.29e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SERPINE1—stomach cancer	8.06e-06	9.29e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—stomach cancer	7.98e-06	9.2e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—stomach cancer	7.97e-06	9.19e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RHOA—stomach cancer	7.9e-06	9.11e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—stomach cancer	7.9e-06	9.11e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—stomach cancer	7.85e-06	9.05e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6R—stomach cancer	7.83e-06	9.03e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOS3—stomach cancer	7.82e-06	9.02e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK1—stomach cancer	7.79e-06	8.99e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—stomach cancer	7.79e-06	8.98e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RHOA—stomach cancer	7.78e-06	8.96e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1B—stomach cancer	7.72e-06	8.9e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOS3—stomach cancer	7.7e-06	8.87e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK1—stomach cancer	7.69e-06	8.86e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—stomach cancer	7.68e-06	8.86e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—stomach cancer	7.66e-06	8.83e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—stomach cancer	7.65e-06	8.81e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—stomach cancer	7.6e-06	8.76e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CD44—stomach cancer	7.55e-06	8.7e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—stomach cancer	7.51e-06	8.66e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1B—stomach cancer	7.47e-06	8.61e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—stomach cancer	7.45e-06	8.59e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—stomach cancer	7.36e-06	8.49e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—stomach cancer	7.36e-06	8.49e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—JUN—stomach cancer	7.35e-06	8.47e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—stomach cancer	7.34e-06	8.47e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SERPINE1—stomach cancer	7.33e-06	8.45e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—stomach cancer	7.33e-06	8.45e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—stomach cancer	7.32e-06	8.43e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—stomach cancer	7.27e-06	8.38e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—stomach cancer	7.26e-06	8.37e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—stomach cancer	7.2e-06	8.3e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—stomach cancer	7.15e-06	8.24e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—stomach cancer	7.12e-06	8.21e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—stomach cancer	7.12e-06	8.21e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—JUN—stomach cancer	7.11e-06	8.19e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RHOA—stomach cancer	7.07e-06	8.16e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOS3—stomach cancer	7e-06	8.07e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK8—stomach cancer	6.95e-06	8.01e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—stomach cancer	6.94e-06	8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—stomach cancer	6.92e-06	7.97e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—stomach cancer	6.89e-06	7.95e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—stomach cancer	6.89e-06	7.94e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—stomach cancer	6.83e-06	7.87e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—stomach cancer	6.78e-06	7.82e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1B—stomach cancer	6.77e-06	7.81e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—stomach cancer	6.76e-06	7.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK8—stomach cancer	6.73e-06	7.75e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—stomach cancer	6.67e-06	7.69e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1B—stomach cancer	6.67e-06	7.69e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—stomach cancer	6.6e-06	7.61e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—stomach cancer	6.55e-06	7.55e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—stomach cancer	6.54e-06	7.54e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—stomach cancer	6.49e-06	7.48e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—stomach cancer	6.46e-06	7.45e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—JUN—stomach cancer	6.45e-06	7.44e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPP2R1A—stomach cancer	6.42e-06	7.4e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—stomach cancer	6.42e-06	7.4e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—stomach cancer	6.36e-06	7.33e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—stomach cancer	6.35e-06	7.33e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—JUN—stomach cancer	6.35e-06	7.32e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—stomach cancer	6.3e-06	7.26e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—stomach cancer	6.27e-06	7.23e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—stomach cancer	6.26e-06	7.21e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—stomach cancer	6.25e-06	7.21e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMOX1—stomach cancer	6.21e-06	7.16e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—stomach cancer	6.21e-06	7.16e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—stomach cancer	6.21e-06	7.16e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—stomach cancer	6.17e-06	7.12e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—stomach cancer	6.17e-06	7.11e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—stomach cancer	6.15e-06	7.09e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—stomach cancer	6.15e-06	7.09e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK8—stomach cancer	6.1e-06	7.04e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK3—stomach cancer	6.07e-06	7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1B—stomach cancer	6.06e-06	6.99e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK8—stomach cancer	6e-06	6.92e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—stomach cancer	5.99e-06	6.91e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—stomach cancer	5.91e-06	6.81e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—stomach cancer	5.9e-06	6.81e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK3—stomach cancer	5.87e-06	6.77e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TYMS—stomach cancer	5.85e-06	6.75e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—stomach cancer	5.8e-06	6.69e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—stomach cancer	5.79e-06	6.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—stomach cancer	5.79e-06	6.67e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK1—stomach cancer	5.78e-06	6.66e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—stomach cancer	5.78e-06	6.66e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—JUN—stomach cancer	5.77e-06	6.66e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—stomach cancer	5.71e-06	6.59e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—stomach cancer	5.63e-06	6.5e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—stomach cancer	5.62e-06	6.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—stomach cancer	5.6e-06	6.45e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK1—stomach cancer	5.59e-06	6.44e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—stomach cancer	5.59e-06	6.44e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—stomach cancer	5.58e-06	6.43e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—stomach cancer	5.54e-06	6.39e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—stomach cancer	5.49e-06	6.33e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK8—stomach cancer	5.46e-06	6.3e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—stomach cancer	5.46e-06	6.29e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ERCC2—stomach cancer	5.44e-06	6.27e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK3—stomach cancer	5.33e-06	6.15e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—stomach cancer	5.28e-06	6.09e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK3—stomach cancer	5.24e-06	6.05e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—stomach cancer	5.18e-06	5.98e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MTHFR—stomach cancer	5.11e-06	5.9e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—stomach cancer	5.1e-06	5.88e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK1—stomach cancer	5.07e-06	5.85e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—stomach cancer	5.07e-06	5.85e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—stomach cancer	5.04e-06	5.82e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—stomach cancer	5.01e-06	5.78e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—stomach cancer	4.99e-06	5.76e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK1—stomach cancer	4.99e-06	5.75e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—stomach cancer	4.99e-06	5.75e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—stomach cancer	4.85e-06	5.59e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—stomach cancer	4.85e-06	5.59e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—stomach cancer	4.79e-06	5.52e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK3—stomach cancer	4.77e-06	5.5e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CAV1—stomach cancer	4.72e-06	5.44e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—stomach cancer	4.71e-06	5.43e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—stomach cancer	4.71e-06	5.43e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOA1—stomach cancer	4.71e-06	5.43e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—stomach cancer	4.69e-06	5.41e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—stomach cancer	4.64e-06	5.35e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—stomach cancer	4.64e-06	5.35e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK1—stomach cancer	4.54e-06	5.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—stomach cancer	4.54e-06	5.23e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—stomach cancer	4.49e-06	5.17e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—stomach cancer	4.44e-06	5.12e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—stomach cancer	4.4e-06	5.07e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—stomach cancer	4.33e-06	4.99e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—stomach cancer	4.29e-06	4.95e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—stomach cancer	4.29e-06	4.94e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—stomach cancer	4.26e-06	4.91e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—stomach cancer	4.19e-06	4.83e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—stomach cancer	4.15e-06	4.78e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—stomach cancer	4.07e-06	4.69e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—stomach cancer	4.01e-06	4.62e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—stomach cancer	3.94e-06	4.54e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—stomach cancer	3.9e-06	4.49e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—stomach cancer	3.83e-06	4.42e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—stomach cancer	3.81e-06	4.39e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—stomach cancer	3.73e-06	4.3e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—stomach cancer	3.64e-06	4.2e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NOS3—stomach cancer	3.57e-06	4.11e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—stomach cancer	3.49e-06	4.02e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—stomach cancer	3.26e-06	3.76e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—stomach cancer	2.01e-06	2.31e-05	CbGpPWpGaD
